查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1439224

迷走神经刺激器 (VNS) - 全球市场回顾、竞争格局、市场预测 (2030)

Vagus Nerve Stimulator (VNS) - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

2023年，全球迷走神经刺激器（VNS）市场规模将达到4.2622亿美元，到2030年将达到7.1717亿美元，2024-2030年预测期间复合年增长率为9.06%，预计增长。 对迷走神经刺激器（VNS）的需求迅速增加，主要是因为癫痫、偏头痛和其他头痛等神经系统疾病的盛行率不断增加，并且 VNS 疗法已被证明是有效的。抗药性出现时的联合治疗，以及越来越多的研究调查VNS 对于其批准适应症以外的适应症（例如耳鸣和慢性疼痛）的影响；技术进步导致新产品（例如非侵入性VNS 设备）的开发在2024-2030 年预测期内促进迷走神经刺激器(VNS) 市场的成长。

迷走神经刺激器（VNS）的市场动态

由于多种原因，迷走神经刺激市场的产品需求正在增加，其中神经系统疾病盛行率的上升是主要原因之一。 根据世界卫生组织 (WHO) (2023) 引用的数据，全球有超过 5,000 万人患有癫痫症。 此外，一般人群中患有活动性癫痫（即癫痫发作持续或需要治疗）的比例估计为每 1,000 人 4 至 10 人。 此外，世界卫生组织的另一份情况说明书指出，全球约有 2.64 亿人患有忧郁症。 癫痫和忧郁症等神经系统疾病通常会使人极度虚弱，并且难以透过药物治疗。 此外，此类适应症的药物治疗通常与严重的副作用有关。

因此，迷走神经刺激等替代方法是抗药性忧郁症和癫痫病例的首选治疗方法，也可以与药物治疗相结合，为患者提供协同效应，目前正在这样做。 据报导，迷走神经刺激对于预防癫痫患者的癫痫发作具有正面的效果。 此外，在许多研究中，接受迷走神经刺激治疗癫痫的患者的忧郁症临床改善与 VNS 对癫痫发作的影响无关，非精神病性重度忧郁症患者的忧郁症改善了 40-50%。已经有了一些改善。

此外，随着有关 VNS 治疗的更多积极结果的报道，更多的研究正在各个疾病领域进行，这可能会在未来进一步扩大迷走神经刺激的应用。 例如，多项研究正在进行中，调查 VNS 对耳鸣、肠躁症和慢性疼痛的影响。 这进一步为 VNS 市场在不久的将来出现重大进步提供了机会。

然而，与手术相关的併发症和这些设备的高成本可能是阻碍迷走神经刺激器（VNS）市场成长的因素。

除上述因素外，由于 COVID-19 大流行，迷走神经刺激器 (VNS) 市场正处于缓慢增长期。 全球各政府实施的锁定是为了遏制Covid-19的传播，导致所有医疗专业的各种手术和门诊就诊，尤其是影响选修程序。我做到了。 因此，随着 VNS 手术被归类为选择性手术，对 VNS 设备的需求显着减少。 此外，全球封锁的实施也不同程度地进一步影响了采购和供应链。 然而，各种COVID-19疫苗的批准和大规模疫苗接种计划的实施为迷走神经刺激器（VNS）需求的復苏铺平了道路，在预测期内对迷走神经刺激器（VNS）市场产生了积极影响。提供了成长的环境。

本报告研究和分析了全球迷走神经刺激器 (VNS) 市场，提供市场规模和预测、驱动因素和挑战、公司和产品概况等。

目录

第一章迷走神经刺激器 (VNS) 市场报告简介

第 2 章迷走神经刺激器 (VNS) 市场执行摘要

  • 调查范围
  • 市场概览
  • 竞争评估
  • 财务基准

第三章监理与专利分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第四章迷走神经刺激器（VNS）市场主要因素分析

  • 迷走神经刺激器 (VNS) 市场驱动因素
    • 神经系统疾病的盛行率不断上升
    • 更重视替代疗法
    • 日益关注扩大 VNS 治疗的应用领域
    • 产品开发方面的技术进步
  • 迷走神经刺激器（VNS）市场限制因素与挑战
    • 与手术有关的併发症
    • 设备成本高
  • 迷走神经刺激器 (VNS) 市场机会
    • 改进产品设计
    • 推出针对新兴市场的产品

第五章迷走神经刺激器 (VNS) 市场波特五力分析

第六章 COVID-19 对迷走神经刺激器 (VNS) 市场的影响分析

第七章迷走神经刺激器（VNS）市场布局

  • 依产品类型
    • 侵入式 VNS 设备
    • 非侵入性 VNS 设备
  • 依用途
    • 偏头痛
    • 癫痫
    • 忧郁症
    • 其他
  • 按最终用户
    • 医院
    • 专科诊所
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 其他领域

第 8 章迷走神经刺激器 (VNS) 市场公司与产品概况

  • LivaNova
  • Soterix Medical Inc
  • MicroTransponder Inc
  • Parasym Ltd
  • electroCore
  • tVNS Technologies GmbH

第9章KOL浏览量

第 10 章专案方法

第 11 章关于 DelveInsight

第 12 章免责声明与联络资讯

Product Code: DIMDCL0009

Vagus Nerve Stimulators Market By Product Type (Invasive VNS Devices And Non-Invasive VNS Devices), By Application (Migraine, Epilepsy, Depression, And Others), By End User (Hospitals, Specialty Clinics, And Others), and by geography is expected to grow at a steady CAGR (forecast period- 2024-2030) owing to increasing prevalence of neurological disorders and growing popularity of non-invasive VNS devices

Global vagus nerve stimulators market was valued at USD 426.22 million in 2023, growing at a CAGR of 9.06% during the forecast period from 2024 to 2030 to reach USD 717.17 million by 2030. The demand for vagus nerve stimulators is witnessing a surge primarily due to the rising prevalence of neurological diseases such as epilepsy, headache disorders such as migraine, and others that have proven to receive benefit from the VNS therapy, increasing popularity of VNS therapy as an alternative or even conjunctive treatment in cases where drug resistance develops, growing research in studying the effects of VNS on other indications such as tinnitus and chronic pain besides the approved ones, technological advancements leading to the development of new products such as non-invasive VNS devices thereby boosting the growth of the vagus nerve stimulators market during the forecast period from 2024-2030.

Vagus Nerve Stimulators Market Dynamics:

The vagus nerve stimulators market is experiencing an increase in product demand for a variety of reasons with one of the key reasons being the rising prevalence of neurological disorders. As per the data cited by the World Health Organization (WHO) (2023), over 50 million people across the globe suffer from epilepsy. The source further stated that the estimated proportion of the general population with active epilepsy (i.e. persistent seizures or that require treatment) at any given time is between 4 and 10 per 1000 people. Additionally, in another factsheet by the WHO, it was stated that approximately 264 million people suffer from depression globally. Neurological indications such as epilepsy and depression can be extremely debilitating for patients and are often become refractory to pharmacological treatments. Moreover, pharmacological treatments in such indications are often accompanied with severe side-effects.

Owing to these, an alternative approach such as vagus nerve stimulation has been a preferred mode of treatment in drug-resistant cases of depression, epilepsy as well as it is also being administered in combination with pharmacological treatments in order to provide synergistic effect to patients. Vagus nerve stimulation has been reported to provide positive results in terms of preventing seizures in epileptic patients. Additionally, many studies reported that patients who received vagus nerve stimulation for epilepsy, showed clinical improvement with depression unrelated to the effect of the VNS on their seizures with nearly 40-50% improvement in patients with non-psychotic major depression.

Moreover, with more positive results being reported concerning the VNS therapy, more research is being conducted on different disease areas which may further expand the application of vagus nerve stimulation in coming years. For instance, several studies are ongoing in studying the effects of VNS on tinnitus, irritable bowel syndrome, and chronic pain among other indications. This further presents an opportunity for making significant headway in the VNS market in the near future.

However, procedure-related complications and high cost of these devices may be confining factors for the vagus nerve stimulators market growth.

Along with the factors mentioned above, the vagus nerve stimulators market witnessed a period of slow growth due to the COVID-19 pandemic. The lockdown implemented by various governments worldwide to curb the spread of the COVID-19 infection resulted in suspension of various surgeries and outpatient consultations across all medical specialties including specifically impacting elective procedures. This led to a considerable decrease in the demand for VNS devices as VNS procedures were classified under elective procedures. Furthermore, the implementation of global lockdown in varying degrees further affected the procurement and supply chain. However, the approval of various COVID-19 vaccines and the implementation of mass vaccination programs have paved the way for resumption of vagus nerve stimulators demand, thereby providing a positive growth environment for the vagus nerve stimulators market during the forecast period.

Vagus Nerve Stimulators Market Segment Analysis:

Vagus Nerve Stimulators Market by Product Type (Invasive VNS Devices and Non-Invasive VNS Devices), by Application (Migraine, Epilepsy, Depression, and Others), by End User (Hospitals, Specialty Clinics, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the product segment of the vagus nerve stimulators market, the non-invasive VNS devices category is expected to register a healthy CAGR in the vagus nerve stimulators market during the forecast period. This can be attributed to the advantages offered by these devices over their counterparts. Implantable VNS devices are often associated with adverse events encompassing both-the surgical procedure and the electrical stimulation itself. Therefore, the non-invasive VNS (nVNS) devices were developed with the aim to address the shortcomings associated with the invasive VNS devices.

Subsequently, non-invasive VNS (nVNS) delivery options that eliminate the need for surgical implantation were developed. These VNS delivery systems help in avoiding surgery-related adverse events such as infections and cardiac complications. Additionally, nVNS devices further help in addressing limitations of implantable VNS devices such as the continuous on-off stimulation cycle of implantable devices as the nVNS devices can be adjusted to balance tolerability and efficacy by end users. A few of the non-invasive vagus nerve stimulators that are currently available for commercial use are gammaCore, Sapphire by electroCore and Parasym device by Parasym Ltd.

Thus, all the above-listed factors are likely to propel the growth of the market for non-invasive VNS devices, ultimately driving the growth of the overall vagus nerve stimulators market.

North America is expected to dominate the overall Vagus Nerve Stimulators Market:

Among all the regions, North America is estimated to account for the largest share in the vagus nerve stimulators market. The key driving factors of the North America vagus nerve stimulators market are high prevalence of epilepsy, depression in the region, increasing disposable income, and rising investments and big collaborative expansions by key players in the region. Moreover, the conducive regulatory environment in the region are expected to establish the dominance of North America VNS market in the overall global landscape.

One of the key driving factors of the United States vagus nerve stimulators market is the interplay of various factors in the country. This domination is due to the increase in epileptic population, increasing prevalence of headache disorders such as migraine, and depression in the country. Furthermore, extensive research and development activities pertaining to product development and conducive regulatory environment further helps product manufacturers to generate more revenue from the country.

For instance, as per the data cited by the National Headache Association (2023), approximately 40 million American are living with migraine and headache disorders in the country. Therefore, the presence of large patient population suffering from migraine and headache disorders correlates to the presence of a potential patient population that may resort to using VNS devices as a treatment method, thus driving the product demand in the nation. Moreover, increasing epileptic population is also expected to drive the demand for vagus nerve stimulators in the country. For instance, as per the data provided by the Centers for Disease Control and Prevention (2023), in 2015, about 3.4 million people across the nation were diagnosed with epilepsy of which 470,000 were children. As mentioned by the International League Against Epilepsy, one-third of epileptic patient population continue to have seizures despite being on anti-seizure medication. This presents another opportunity for VNS devices as they have been reported and approved for medical use for treating drug-resistant epilepsy.

Also, advanced product launches and commercialization agreements among the key companies are further expected to fuel the market. For instance, in August 2022, the US Food and Drug Administration approved drug-free rehabilitation system intended to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke-a stroke caused by a blockage of blood flow to the brain with long-lasting symptoms the first-of-its kind VNS device- the MicroTransponder Vivistim Paired VNS System. Thus, the interplay of all the aforementioned factors are likely to fuel the market growth of vagus nerve stimulators in the United States during the forecast period

Besides United States, product development activities in Canada also provide supportive growth opportunities for the North America vagus nerve stimulators market. For instance, the Canadian Health regulatory body Health Canada authorized the Dolphin vagus nerve stimulator for emergency use in the treatment of COVID-19 induced acute respiratory distress syndrome.

Thus, all these activities point towards the presence of conducive growth environment in the North American region, ultimately influencing the market growth of this regional market.

Vagus Nerve Stimulators Market Key Players:

Some of the key market players operating in the vagus nerve stimulators market includes LivaNova, Soterix Medical Inc, MicroTransponder Inc, Parasym Ltd, electroCore, tVNS Technologies GmbH and others.

Recent Developmental Activities in Vagus Nerve Stimulators Market:

In August 2022, the US Food and Drug Administration approved the MicroTransponder Vivistim Paired VNS System, a one-of-its-kind, drug rehabilitation system with the intention to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke.

In March 2020, LivaNova received the CE Mark approval for their Vagus Nerve Stimulation Therapy® (VNS Therapy) System, Symmetry(TM) for difficult-to-treat depression.

Key Takeaways from the Vagus Nerve Stimulators Market Report Study

Market size analysis for current vagus nerve stimulators market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the vagus nerve stimulators market.

Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years

Key companies dominating the global vagus nerve stimulators market.

Various opportunities available for the other competitor in the vagus nerve stimulators market space.

What are the top performing segments in 2023? How these segments will perform in 2030.

Which is the top-performing regions and countries in the current vagus nerve stimulators market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for vagus nerve stimulators market growth in the coming future?

Target Audience who can be benefited from this Vagus Nerve Stimulators Market Report Study

Vagus nerve stimulators products providers

Research organizations and consulting companies

Vagus nerve stimulators-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in vagus nerve stimulators

Various End-users who want to know more about the vaginal rejuvenation systems market and latest technological developments in the vaginal rejuvenation systems market.

Frequently Asked Questions for Vagus Nerve Stimulators Market:

1. What is a Vagus Nerve Stimulator?

A vagus nerve stimulator is a pacemaker like device which comes with an implantable programmable generator that is implanted in the chest wall and delivers electrical impusles to the vagus nerve in the neck thereby stimulating the vagus nerve and providing relief to patients.

2. What is the market for Global Vagus Nerve Stimulators?

Global vagus nerve stimulators market was valued at USD 426.22 million in 2023, growing at a CAGR of 9.06% during the forecast period from 2024 to 2030 to reach USD 717.17 million by 2030.

3. What are the drivers for Global Vagus Nerve Stimulators Market?

The demand for vagus nerve stimulators is witnessing a surge primarily due to the rising prevalence of neurological diseases such as epilepsy, headache disorders such as migraine, and others that have proven to receive benefit from the VNS therapy, increasing popularity of VNS therapy as an alternative or even conjunctive treatment in cases where drug resistance develops, growing research in studying the effects of VNS on other indications besides the approved ones, technological advancements leading to the development of new products such as non-invasive VNS devices thereby boosting the growth of the vagus nerve stimulators market during the forecast period from 2024-2030.

4. Who are the key players operating in Global Vagus Nerve Stimulators Market?

Some of the key market players operating in the vagus nerve stimulators market includes LivaNova, Soterix Medical Inc, MicroTransponder Inc, Parasym Ltd, electroCore, tVNS Technologies GmbH and others.

5. Which region has the highest share in Vagus Nerve Stimulators market?

Among all the regions, North America is estimated to account for the largest share in the vagus nerve stimulators market. The key driving factors of the North America vagus nerve stimulators market are high prevalence of epilepsy, depression in the region, increasing disposable income, and rising investments and big collaborative expansions by key players in the region. Moreover, the conducive regulatory environment in the region are expected to establish the dominance of North America VNS market in the overall global landscape.

Table of Contents

1.Vagus Nerve Stimulators Market Report Introduction

2.Vagus Nerve Stimulators Market Executive Summary

  • 2.1 Scope of the Study
  • 2.2 Market at Glance
  • 2.3 Competitive Assessment
  • 2.4 Financial Benchmarking

3. Regulatory and Patent Analysis

  • 3.1 The United States
  • 3.2 Europe
  • 3.3 Japan
  • 3.4 China

4. Vagus Nerve Stimulators Market Key Factors Analysis

  • 4.1 Vagus Nerve Stimulators Market Drivers
    • 4.1.1 Rising Prevalence of Neurological Disorders
    • 4.1.2 Increasing Focus Toward Alternative Treatments
    • 4.1.3 Growing Focus on Expanding Application Area of VNS Therapy
    • 4.1.4 Technological Advancements in Product Development
  • 4.2 Vagus Nerve Stimulators Market Restraints and Challenges
    • 4.2.1 Procedure-Related Complications
    • 4.2.2 High Cost of Devices
  • 4.3 Vagus Nerve Stimulators Market Opportunities
    • 4.3.1 Improving on the Product Design
    • 4.3.2 Targeting Emerging Markets for Product Launches

5. Vagus Nerve Stimulators Market Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers
  • 5.2 Bargaining Power of Consumers
  • 5.3 Threat of New Entrants
  • 5.4 Threat of Substitutes
  • 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on Vagus Nerve Stimulators Market

7. Vagus Nerve Stimulators Market Layout

  • 7.1 By Product Type
    • 7.1.1 Invasive VNS Devices
    • 7.1.2 Non-invasive VNS Devices
  • 7.2 By Application
    • 7.2.1 Migraine
    • 7.2.2 Epilepsy
    • 7.2.3 Depression
    • 7.2.4 Others
  • 7.3 By End User
    • 7.3.1 Hospitals
    • 7.3.2 Specialty Clinics
    • 7.3.3 Others
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 North America Vagus Nerve Stimulators Market, by Country
      • 7.4.1.4.1 United States
      • 7.4.1.4.2 Canada
      • 7.4.1.4.3 Mexico
    • 7.4.2 Europe
      • 7.4.2.1 Europe Vagus Nerve Stimulators Market, by Country
      • 7.4.2.4.1 France
      • 7.4.2.4.2 Germany
      • 7.4.2.4.3 United Kingdom
      • 7.4.2.4.4 Italy
      • 7.4.2.4.5 Spain
      • 7.4.2.2.6 Russia
      • 7.4.2.2.7 Rest of Europe
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 Asia-Pacific Vagus Nerve Stimulators Market, by Country
      • 7.4.3.4.1 China
      • 7.4.3.4.2 Japan
      • 7.4.3.4.3 India
      • 7.4.3.4.4 Australia
      • 7.4.3.4.5 South Korea
      • 7.4.3.4.6 Rest of Asia Pacific
    • 7.4.4 Rest of the World (RoW)
      • 7.4.4.1 RoW Vagus Nerve Stimulators Market, by Region
      • 7.4.4.4.1 Middle East
      • 7.4.4.4.2 Africa
      • 7.4.4.4.3 South America

8. Vagus Nerve Stimulators Market Company and Product Profiles

  • 8.1 LivaNova
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4 Product Listing
    • 8.1.5. Entropy
  • 8.2 Soterix Medical Inc
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4 Product Listing
    • 8.2.5. Entropy
  • 8.3 MicroTransponder Inc
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4 Product Listing
    • 8.3.5. Entropy
  • 8.4 Parasym Ltd
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4 Product Listing
    • 8.4.5. Entropy
  • 8.5 electroCore
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6 tVNS Technologies GmbH
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4 Product Listing
    • 8.6.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1 Competitive Analysis
  • Table 2 COVID-19 Impact Analysis on Vagus Nerve Stimulators Market
  • Table 3 Vagus Nerve Stimulators Market in Global (2021-2030)
  • Table 4 Vagus Nerve Stimulators Market in Global by Product Type (2021-2030)
  • Table 5 Vagus Nerve Stimulators Market in Global by Application (2021-2030)
  • Table 6 Vagus Nerve Stimulators Market in Global by End User (2021-2030)
  • Table 7 Vagus Nerve Stimulators Market in Global by Geography (2021-2030)
  • Table 8 Vagus Nerve Stimulators Market in North America (2021-2030)
  • Table 9 Vagus Nerve Stimulators Market in North America by Product Type (2021-2030)
  • Table 10 Vagus Nerve Stimulators Market in North America by Application (2021-2030)
  • Table 11 Vagus Nerve Stimulators Market in North America by End User (2021-2030)
  • Table 12 Vagus Nerve Stimulators Market in North America by Country (2021-2030)
  • Table 13 Vagus Nerve Stimulators Market in the US (2021-2030)
  • Table 14 Vagus Nerve Stimulators Market in Canada (2021-2030)
  • Table 15 Vagus Nerve Stimulators Market in Mexico (2021-2030)
  • Table 16 Vagus Nerve Stimulators Market in Europe (2021-2030)
  • Table 17 Vagus Nerve Stimulators Market in Europe by Product Type (2021-2030)
  • Table 18 Vagus Nerve Stimulators Market in Europe by Application (2021-2030)
  • Table 19 Vagus Nerve Stimulators Market in Europe by End User (2021-2030)
  • Table 20 Vagus Nerve Stimulators Market in Europe by Country (2021-2030)
  • Table 21 Vagus Nerve Stimulators Market in France (2021-2030)
  • Table 22 Vagus Nerve Stimulators Market in Germany (2021-2030)
  • Table 23 Vagus Nerve Stimulators Market in the United Kingdom (2021-2030)
  • Table 24 Vagus Nerve Stimulators Market in Italy (2021-2030)
  • Table 25 Vagus Nerve Stimulators Market in Spain (2021-2030)
  • Table 26 Vagus Nerve Stimulators Market in Russia (2021-2030)
  • Table 27 Vagus Nerve Stimulators Market in Rest of Europe (2021-2030)
  • Table 28 Vagus Nerve Stimulators Market in APAC (2021-2030)
  • Table 29 Vagus Nerve Stimulators Market in APAC by Product Type (2021-2030)
  • Table 30 Vagus Nerve Stimulators Market in APAC by Application (2021-2030)
  • Table 31 Vagus Nerve Stimulators Market in APAC by End User (2021-2030)
  • Table 32 Vagus Nerve Stimulators Market in APAC by Country (2021-2030)
  • Table 33 Vagus Nerve Stimulators Market in China (2021-2030)
  • Table 34 Vagus Nerve Stimulators Market in Japan (2021-2030)
  • Table 35 Vagus Nerve Stimulators Market in India (2021-2030)
  • Table 36 Vagus Nerve Stimulators Market in Australia (2021-2030)
  • Table 37 Vagus Nerve Stimulators Market in South Korea (2021-2030)
  • Table 38 Vagus Nerve Stimulators Market in Rest of APAC (2021-2030)
  • Table 39 Vagus Nerve Stimulators Market in Rest of World (2021-2030)
  • Table 40 Vagus Nerve Stimulators Market in RoW by Product Type (2021-2030)
  • Table 41 Vagus Nerve Stimulators Market in RoW by Application (2021-2030)
  • Table 42 Vagus Nerve Stimulators Market in RoW by End User (2021-2030)
  • Table 43 Vagus Nerve Stimulators Market in RoW by Region (2021-2030)
  • Table 44 Vagus Nerve Stimulators Market in Middle East (2021-2030)
  • Table 45 Vagus Nerve Stimulators Market in Africa (2021-2030)
  • Table 46 Vagus Nerve Stimulators Market in South America (2021-2030)

List of Figures

Figures 1 Competitive Analysis

Figures 2 COVID-19 Impact Analysis on Vagus Nerve Stimulators Market

Figures 3 Vagus Nerve Stimulators Market in Global (2021-2030)

Figures 4 Vagus Nerve Stimulators Market in Global by Product Type (2021-2030)

Figures 5 Vagus Nerve Stimulators Market in Global by Application (2021-2030)

Figures 6 Vagus Nerve Stimulators Market in Global by End User (2021-2030)

Figures 7 Vagus Nerve Stimulators Market in Global by Geography (2021-2030)

Figures 8 Vagus Nerve Stimulators Market in North America (2021-2030)

Figures 9 Vagus Nerve Stimulators Market in North America by Product Type (2021-2030)

Figures 10 Vagus Nerve Stimulators Market in North America by Application (2021-2030)

Figures 11 Vagus Nerve Stimulators Market in North America by End User (2021-2030)

Figures 12 Vagus Nerve Stimulators Market in North America by Country (2021-2030)

Figures 13 Vagus Nerve Stimulators Market in the US (2021-2030)

Figures 14 Vagus Nerve Stimulators Market in Canada (2021-2030)

Figures 15 Vagus Nerve Stimulators Market in Mexico (2021-2030)

Figures 16 Vagus Nerve Stimulators Market in Europe (2021-2030)

Figures 17 Vagus Nerve Stimulators Market in Europe by Product Type (2021-2030)

Figures 18 Vagus Nerve Stimulators Market in Europe by Application (2021-2030)

Figures 19 Vagus Nerve Stimulators Market in Europe by End User (2021-2030)

Figures 20 Vagus Nerve Stimulators Market in Europe by Country (2021-2030)

Figures 21 Vagus Nerve Stimulators Market in France (2021-2030)

Figures 22 Vagus Nerve Stimulators Market in Germany (2021-2030)

Figures 23 Vagus Nerve Stimulators Market in the United Kingdom (2021-2030)

Figures 24 Vagus Nerve Stimulators Market in Italy (2021-2030)

Figures 25 Vagus Nerve Stimulators Market in Spain (2021-2030)

Figures 26 Vagus Nerve Stimulators Market in Russia (2021-2030)

Figures 27 Vagus Nerve Stimulators Market in Rest of Europe (2021-2030)

Figures 28 Vagus Nerve Stimulators Market in APAC (2021-2030)

Figures 29 Vagus Nerve Stimulators Market in APAC by Product Type (2021-2030)

Figures 30 Vagus Nerve Stimulators Market in APAC by Application (2021-2030)

Figures 31 Vagus Nerve Stimulators Market in APAC by End User (2021-2030)

Figures 32 Vagus Nerve Stimulators Market in APAC by Country (2021-2030)

Figures 33 Vagus Nerve Stimulators Market in China (2021-2030)

Figures 34 Vagus Nerve Stimulators Market in Japan (2021-2030)

Figures 35 Vagus Nerve Stimulators Market in India (2021-2030)

Figures 36 Vagus Nerve Stimulators Market in Australia (2021-2030)

Figures 37 Vagus Nerve Stimulators Market in South Korea (2021-2030)

Figures 38 Vagus Nerve Stimulators Market in Rest of APAC (2021-2030)

Figures 39 Vagus Nerve Stimulators Market in Rest of World (2021-2030)

Figures 40 Vagus Nerve Stimulators Market in RoW by Product Type (2021-2030)

Figures 41 Vagus Nerve Stimulators Market in RoW by Application (2021-2030)

Figures 42 Vagus Nerve Stimulators Market in RoW by End User (2021-2030)

Figures 43 Vagus Nerve Stimulators Market in RoW by Region (2021-2030)

Figures 44 Vagus Nerve Stimulators Market in Middle East (2021-2030)

Figures 45 Vagus Nerve Stimulators Market in Africa (2021-2030)

Figures 46 Vagus Nerve Stimulators Market in South America (2021-2030)

Figures 47 Market Drivers

Figures 48 Market Barriers

Figures 49 Marker Opportunities

Figures 50 PORTER'S Five Force Analysis